On November 6, 2026 Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, reported its recent updates and financial results for the quarter ended September 30, 2026.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"We are continuing to pursue all strategic options to maximize stockholder value, including within our own rare disease portfolio. This includes advancement of SGX945 (dusquetide) for Behçet’s disease, which showed encouraging signs of biological activity and was generally safe and well-tolerated in a small, open-label Phase 2a proof-of-concept study, as well as our ThermoVax heat-stable vaccine platform," stated Christopher J. Schaber, PhD, President and Chief Executive Officer of Soligenix. "With approximately $9.0 million in cash and cash equivalents as of September 30, 2026, which we believe is sufficient to fund our current operating plan into the second quarter of 2028, we are evaluating a number of potential opportunities, including but not limited to partnership, licensing, merger and acquisition, government grants and contracts, while advancing our existing pipeline. Maintaining our Nasdaq listing is also an important strategic asset that supports these efforts by preserving access to the public capital markets, enhancing our attractiveness to potential strategic partners and acquirers, and providing additional flexibility as we evaluate these opportunities."
Financial Results – Quarter Ended September 30, 2026
Soligenix had no revenue for the quarters ended September 30, 2026 and 2025.
Soligenix’s net loss was $1.1 million, or ($0.05) per share, for the quarter ended September 30, 2026, compared to $2.5 million, or ($0.58) per share, for the same prior year period. This decrease in net loss was primarily due to a decrease in research and development expenses associated with the terminated FLASH2 trial and related HyBryte development activities, and a gain on extinguishment of vendor liabilities.
Research and development expenses were $0.4 million for the quarter ended September 30, 2026, as compared to $1.6 million for the same period in 2025. The decrease was primarily due to decreases in costs associated with the terminated FLASH2 trial and related HyBryte development activities.
General and administrative expenses were $1.0 million for the quarter ended September 30, 2026 as compared to $1.0 million for the same period in 2025, relatively flat with a de minimis increase.
As of September 30, 2026, the Company had cash and cash equivalents of approximately $9.0 million.
(Press release, Soligenix, NOV 6, 2026, View Source [SID1234674398])